Literature DB >> 2833919

Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin II induced hypertension for treatment of hepatocellular carcinoma.

S Onohara1, H Kobayashi, Y Itoh, S Shinohara.   

Abstract

Cis-diamminedichloroplatinum II (CDDP; 52-169 mg/m2) mixed with angiotensin II (1.5-10 micrograms/min) was infused into the hepatic artery in 33 patients with hepatocellular carcinoma. Simultaneously, sodium thiosulfate (10-50 g) was administered intravenously in order to reduce the systemic toxicity of CDDP. Over 50 per cent reduction in tumor size was obtained in 18 patients (55%). Complete response was achieved in 4 patients (12%). Serum alpha-fetoprotein (AFP) levels decreased by more than 75 per cent in 10 of 18 patients in whom the previous AFP level was more than 200 ng/ml. The one year survival rate was estimated at 61 per cent by the Kaplan-Meier method. Alimentary symptoms (nausea, vomiting) were mild or non-existent in nearly 90 per cent of treatments. Peptic ulcer and abdominal pain were manifested in small numbers. Severe changes in the laboratory data were not observed. High dosage arterial infusion of CDDP and angiotensin II and intravenous injection of sodium thiosulfate was well tolerated and gave effective therapy in hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2833919

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  10 in total

1.  Polymer-coated albumin microspheres as carriers for intravascular tumour targeting of cisplatin.

Authors:  R Verrijk; I J Smolders; J G McVie; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  Hepatocellular carcinoma.

Authors:  S Badvie
Journal:  Postgrad Med J       Date:  2000-01       Impact factor: 2.401

3.  Pharmacokinetics of regional angiotensin-II: a novel biologic response modifier.

Authors:  Y Wu; J V Sitzmann
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

Review 4.  Regional cancer chemotherapy for advanced stage hepatocellular carcinoma.

Authors:  B I Carr; S Iwatsuki; T E Starzl; R Selby; J Madariaga
Journal:  J Surg Oncol Suppl       Date:  1993

Review 5.  Practical considerations in the treatment of hepatocellular carcinoma.

Authors:  M Colleoni; R A Audisio; F De Braud; N Fazio; G Martinelli; A Goldhirsch
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

6.  Increased therapeutic effect on metastatic liver tumors in rats of two-route chemotherapy using cis-diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, with temporary clamping of the abdominal aorta.

Authors:  K Hasuda; H Kobayashi; K Aoki; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

7.  Comparison of the anticancer effect of ADMOS alone and ADMOS with CDDP in the treatment of hepatocellular carcinoma by intra-arterial injection.

Authors:  K Ikeda; H Inoue; T Yano; H Kobayashi; M Nakajo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Transarterial internal radiation therapy with I-131 Lipiodol for multifocal hepatocellular carcinoma: immediate and long-term results.

Authors:  Y Kajiya; H Kobayashi; M Nakajo
Journal:  Cardiovasc Intervent Radiol       Date:  1993 May-Jun       Impact factor: 2.740

9.  Decreased angiotensin II receptors mediate decreased vascular response in hepatocellular cancer.

Authors:  Y Wu; P A Cahill; J V Sitzmann
Journal:  Ann Surg       Date:  1996-02       Impact factor: 12.969

10.  Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.

Authors:  M Schmidinger; C Wenzel; G J Locker; F Muehlbacher; R Steininger; M Gnant; R Crevenna; A C Budinsky
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.